{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:35:09Z","timestamp":1792794909352,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Stanley Medical Research Institue","award":["# 07-1690"],"award-info":[{"award-number":["# 07-1690"]}],"id":[{"id":"https:\/\/ror.org\/01pj5nn22","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cognitive deficits are a central feature of schizophrenia for which there are not any established pharmacological treatments. Antipsychotics are the mainstay of schizophrenia therapy but the effects of these and other psychotropic medications on the cognitive functioning of people schizophrenia have not been extensively studied in routine real-world settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design<\/jats:title>\n                    <jats:p>A total of 869 people with schizophrenia receiving community-based care were assessed on a cognitive battery, the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). The machine-learning tool of partialing-out least absolute shrinkage and selection operator (LASSO) regression were used to examine the independent association between the RBANS total and index scores and receipt of individual psychotropic medications considering relevant demographic, clinical, and environmental covariates. In this cross-sectional study, we also examined the effects of medication dosage and some medication combinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Results<\/jats:title>\n                    <jats:p>We found that 4 medications, clozapine, quetiapine, benztropine, and oral haloperidol were each independently associated with significantly reduced cognitive scores compared with people not receiving these medications. Three of the 4 medications, clozapine, haloperidol, and benztropine, showed a significant dose-related relationship with total cognitive score. We also documented further reductions in cognitive functioning in people receiving some pair-wise combinations of these medications. Reduced memory was the domain most associated with these medications, especially among people receiving clozapine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Prescribers may consider minimizing doses and limiting the administration of combinations of the identified medications. Interventions should be further developed for people with schizophrenia to improve their cognitive functioning and quality of life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/schbul\/sbaf047","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T08:42:43Z","timestamp":1742719363000},"source":"Crossref","is-referenced-by-count":3,"title":["The Association Between Psychotropic Medications and Cognitive Functioning in a Real-World Cohort of 869 Individuals with Schizophrenia"],"prefix":"10.1093","volume":"52","author":[{"given":"Faith","family":"Dickerson","sequence":"first","affiliation":[{"name":"The Stanley Research Program at Sheppard Pratt , Baltimore, MD 21204 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Origoni","sequence":"additional","affiliation":[{"name":"The Stanley Research Program at Sheppard Pratt , Baltimore, MD 21204 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Katsafanas","sequence":"additional","affiliation":[{"name":"The Stanley Research Program at Sheppard Pratt , Baltimore, MD 21204 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Rowe","sequence":"additional","affiliation":[{"name":"The Stanley Research Program at Sheppard Pratt , Baltimore, MD 21204 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabahat","family":"Khan","sequence":"additional","affiliation":[{"name":"The Stanley Research Program at Sheppard Pratt , Baltimore, MD 21204 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allana Therese","family":"Calahatian","sequence":"additional","affiliation":[{"name":"The Stanley Research Program at Sheppard Pratt , Baltimore, MD 21204 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Mukhtar","sequence":"additional","affiliation":[{"name":"The Stanley Research Program at Sheppard Pratt , Baltimore, MD 21204 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Yolken","sequence":"additional","affiliation":[{"name":"The Stanley Neurovirology Laboratory, Department of Pediatrics, Johns Hopkins School of Medicine , Baltimore, MD 21205 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"2026011701172997100_CIT0001","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","article-title":"Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment","volume":"28","author":"McCutcheon","year":"2023","journal-title":"Mol Psychiatry."},{"key":"2026011701172997100_CIT0002","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1037\/0894-4105.12.3.426","article-title":"Neurocognitive deficit in schizophrenia: a quantitative review of the evidence","volume":"12","author":"Heinrichs","year":"1998","journal-title":"Neuropsychology."},{"key":"2026011701172997100_CIT0003","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0920-9964(96)00040-0","article-title":"Neurocognitive deficits and social functioning in outpatients with schizophrenia","volume":"21","author":"Dickerson","year":"1996","journal-title":"Schizophr Res."},{"key":"2026011701172997100_CIT0004","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia","volume":"153","author":"Green","year":"1996","journal-title":"Am J Psychiatry."},{"key":"2026011701172997100_CIT0005","doi-asserted-by":"publisher","first-page":"100217","DOI":"10.1016\/j.scog.2021.100217","article-title":"The relationship between cognition and functioning in schizophrenia: A semi-systematic review","volume":"27","author":"Kharawala","year":"2022","journal-title":"Schizophr Res Cogn"},{"key":"2026011701172997100_CIT0006","doi-asserted-by":"publisher","first-page":"e2432401","DOI":"10.1001\/jamanetworkopen.2024.32401","article-title":"Risk factors for natural cause mortality in schizophrenia","volume":"7","author":"Dickerson","year":"2024","journal-title":"JAMA Netw Open."},{"key":"2026011701172997100_CIT0007","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/schbul\/sbp130","article-title":"The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2009","volume":"36","author":"Kreyenbuhl","year":"2010","journal-title":"Schizophr Bull."},{"key":"2026011701172997100_CIT0008","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/acps.12374","article-title":"Second-generation antipsychotic effect on cognition in patients with schizophrenia--a meta-analysis of randomized clinical trials","volume":"131","author":"Nielsen","year":"2015","journal-title":"Acta Psychiatr Scand."},{"key":"2026011701172997100_CIT0009","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3390\/brainsci14080791","article-title":"Treatment of cognitive impairment associated with schizophrenia spectrum disorders: new evidence, challenges, and future perspectives","volume":"14","author":"Calzavara-Pinton","year":"2024","journal-title":"Brain Sci."},{"key":"2026011701172997100_CIT0010","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/jamapsychiatry.2024.2890","article-title":"Antipsychotic drugs and cognitive function: a systematic review and network meta-analysis","volume":"82","author":"Feber","year":"2025","journal-title":"JAMA Psychiatry."},{"key":"2026011701172997100_CIT0011","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.neubiorev.2021.03.028","article-title":"The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: Network meta-analyses of randomized controlled trials","volume":"126","author":"Baldez","year":"2021","journal-title":"Neurosci Biobehav Rev."},{"key":"2026011701172997100_CIT0012","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/schbul\/18.2.273","article-title":"The McLean First-Episode Psychosis Project: six-month recovery and recurrence outcome","volume":"18","author":"Tohen","year":"1992","journal-title":"Schizophr Bull."},{"key":"2026011701172997100_CIT0013","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","article-title":"The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia","volume":"25","author":"Meltzer","year":"1999","journal-title":"Schizophr Bull."},{"key":"2026011701172997100_CIT0014","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1192\/S0007125000293604","article-title":"Cognitive deficit in schizophrenia and its neurochemical basis","volume":"37","author":"Breier","year":"1999","journal-title":"Br J Psychiatry Suppl."},{"key":"2026011701172997100_CIT0015","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch Gen Psychiatry."},{"key":"2026011701172997100_CIT0016","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1176\/appi.ajp.2009.09040497","article-title":"Targeting cognition in schizophrenia research: from etiology to treatment","volume":"166","author":"Goldberg","year":"2009","journal-title":"Am J Psychiatry."},{"key":"2026011701172997100_CIT0017","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1176\/appi.ajp.2020.20081212","article-title":"Anticholinergic medication burden-associated cognitive impairment in schizophrenia","volume":"178","author":"Joshi","year":"2021","journal-title":"Am J Psychiatry."},{"key":"2026011701172997100_CIT0018","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12888-023-04552-y","article-title":"Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia","volume":"23","author":"Haddad","year":"2023","journal-title":"BMC Psychiatry."},{"key":"2026011701172997100_CIT0019","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.schres.2024.02.025","article-title":"Association of antidepressant and benzodiazepine use, and anticholinergic burden with cognitive performance in schizophrenia","volume":"266","author":"M\u00e4kipelto","year":"2024","journal-title":"Schizophr Res."},{"key":"2026011701172997100_CIT0020","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1038\/s41380-024-02503-x","article-title":"Advancing understanding of the mechanisms of antipsychotic-associated cognitive impairment to minimise harm: a call to action","volume":"29","author":"Allott","year":"2024","journal-title":"Mol Psychiatry."},{"key":"2026011701172997100_CIT0021","doi-asserted-by":"publisher","first-page":"CD008016","DOI":"10.1002\/14651858.CD008016.pub3","article-title":"Maintenance treatment with antipsychotic drugs for schizophrenia","volume":"8","author":"Ceraso","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"key":"2026011701172997100_CIT0022","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3389\/fpsyt.2018.00622","article-title":"Antipsychotics, metabolic adverse effects, and cognitive function in schizophrenia","volume":"9","author":"MacKenzie","year":"2018","journal-title":"Front Psychiatry."},{"key":"2026011701172997100_CIT0023","volume-title":"User\u2019s Guide for the SCID-I, Structured Clinical Interview for DSM IV Axis I Disorders","author":"First","year":"1996"},{"key":"2026011701172997100_CIT0024","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull."},{"key":"2026011701172997100_CIT0025","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","article-title":"The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity","volume":"20","author":"Randolph","year":"1998","journal-title":"J Clin Exp Neuropsychol."},{"key":"2026011701172997100_CIT0026","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.schres.2003.10.009","article-title":"Brief cognitive assessment in schizophrenia: normative data for the Repeatable Battery for the Assessment of Neuropsychological Status","volume":"70","author":"Wilk","year":"2004","journal-title":"Schizophr Res."},{"key":"2026011701172997100_CIT0027","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1001\/archpsyc.60.5.466","article-title":"Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia","volume":"60","author":"Dickerson","year":"2003","journal-title":"Arch Gen Psychiatry."},{"key":"2026011701172997100_CIT0028","doi-asserted-by":"publisher","first-page":"113157","DOI":"10.1016\/j.psychres.2020.113157","article-title":"The association between exposure to herpes simplex virus type 1 (HSV-1) and cognitive functioning in schizophrenia: A meta-analysis","volume":"291","author":"Dickerson","year":"2020","journal-title":"Psychiatry Res."},{"key":"2026011701172997100_CIT0029","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1198\/jasa.2009.tm08013","article-title":"Regularization parameter selections via generalized information criterion","volume":"105","author":"Zhang","year":"2010","journal-title":"J Am Stat Assoc."},{"key":"2026011701172997100_CIT0030","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1257\/aer.p20151022","article-title":"Post-selection and post-regulation inference in linear models with many controls and instruments","volume":"105","author":"Chernozhukov","year":"2015","journal-title":"Amer Econ Rev."},{"key":"2026011701172997100_CIT0031","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamani","year":"1995","journal-title":"J Royal Stat Soc, Series B"},{"key":"2026011701172997100_CIT0032","doi-asserted-by":"publisher","first-page":"e069249","DOI":"10.1136\/bmj-2021-069249","article-title":"Validation of prediction models in the presence of competing risks: a guide through modern methods","volume":"377","author":"van Geloven","year":"2022","journal-title":"Bmj."},{"key":"2026011701172997100_CIT0033","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/sim.5937","article-title":"A comparative study of variable selection methods in the context of developing psychiatric screening instruments","volume":"33","author":"Lu","year":"2014","journal-title":"Stat Med."},{"key":"2026011701172997100_CIT0034","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/bs.apha.2017.09.009","article-title":"Unique effects of clozapine: a pharmacological perspective","volume":"82","author":"Khokhar","year":"2018","journal-title":"Adv Pharmacol."},{"key":"2026011701172997100_CIT0035","first-page":"24","article-title":"The effects of clozapine on cognitive functioning in schizophrenia","volume":"60","author":"McGurk","year":"1999","journal-title":"J Clin Psychiatry."},{"key":"2026011701172997100_CIT0036","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/jcp.0000000000001671","article-title":"Long-term outcome of clozapine in treatment-resistant schizophrenia","volume":"43","author":"Lee","year":"2023","journal-title":"J Clin Psychopharmacol."},{"key":"2026011701172997100_CIT0037","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1017\/s1092852922000025","article-title":"Influence of haloperidol and clozapine on the cognitive performance in patients with psychotic disorders: possible attributes","volume":"28","author":"Kar","year":"2023","journal-title":"CNS Spectr."},{"key":"2026011701172997100_CIT0038","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/yic.0000000000000066","article-title":"Cognitive differences in schizophrenia on long-term treatments with clozapine, risperidone and typical antipsychotics","volume":"30","author":"Han","year":"2015","journal-title":"Int Clin Psychopharmacol."},{"key":"2026011701172997100_CIT0039","doi-asserted-by":"publisher","first-page":"112543","DOI":"10.1016\/j.psychres.2019.112543","article-title":"Functioning and cognitive characteristics of clozapine users referred to psychosocial rehabilitation centers: A REHABase cohort study","volume":"281","author":"Verdoux","year":"2019","journal-title":"Psychiatry Res."},{"key":"2026011701172997100_CIT0040","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00228-013-1600-y","article-title":"Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis","volume":"70","author":"D\u00e9sam\u00e9ricq","year":"2014","journal-title":"Eur J Clin Pharmacol."},{"key":"2026011701172997100_CIT0041","doi-asserted-by":"publisher","DOI":"10.47626\/2237-6089-2023-0664","article-title":"Haloperidol versus Second-generation Antipsychotics on the cognitive performance of individuals with schizophrenia and related disorders: pairwise meta-analysis of randomized controlled trials","author":"Baldez","year":"2023","journal-title":"Trends Psychiatry Psychother"},{"key":"2026011701172997100_CIT0042","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/pcn.12088","article-title":"Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function","volume":"68","author":"Ogino","year":"2014","journal-title":"Psychiatry Clin Neurosci."},{"key":"2026011701172997100_CIT0043","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/2045125314553611","article-title":"Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia","volume":"4","author":"Desmarais","year":"2014","journal-title":"Ther Adv Psychopharmacol"},{"key":"2026011701172997100_CIT0044","doi-asserted-by":"publisher","first-page":"e1270","DOI":"10.4088\/JCP.16m11269","article-title":"Reducing anticholinergic medication burden in patients with psychotic or bipolar disorders","volume":"78","author":"Lupu","year":"2017","journal-title":"J Clin Psychiatry."},{"key":"2026011701172997100_CIT0045","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.schres.2014.06.035","article-title":"Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia - An observational 9-year follow-up study","volume":"158","author":"Husa","year":"2014","journal-title":"Schizophr Res."},{"key":"2026011701172997100_CIT0046","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.psychres.2016.10.085","article-title":"Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort","volume":"247","author":"Husa","year":"2017","journal-title":"Psychiatry Res."},{"key":"2026011701172997100_CIT0047","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.bbr.2010.11.033","article-title":"Acetylcholine and attention","volume":"221","author":"Klinkenberg","year":"2011","journal-title":"Behav Brain Res."},{"key":"2026011701172997100_CIT0048","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.schres.2006.03.033","article-title":"Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood","volume":"85","author":"Saeedi","year":"2006","journal-title":"Schizophr Res."},{"key":"2026011701172997100_CIT0049","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.2174\/1570159x15666170630163616","article-title":"Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects","volume":"16","author":"Siafis","year":"2018","journal-title":"Curr Neuropharmacol."},{"key":"2026011701172997100_CIT0050","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.schres.2014.12.033","article-title":"Predictors of neuropsychological effort test performance in schizophrenia","volume":"162","author":"Morra","year":"2015","journal-title":"Schizophr Res."}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/52\/1\/sbaf047\/63129018\/sbaf047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/52\/1\/sbaf047\/63129018\/sbaf047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T06:17:44Z","timestamp":1768630664000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/doi\/10.1093\/schbul\/sbaf047\/8127170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,5,8]]},"published-print":{"date-parts":[[2026,1,16]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbaf047","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,5,8]]},"article-number":"sbaf047"}}